Cost Implications of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
Over $125 billion is spent annually in the United States for cancer treatment.1 Among women in this country, breast cancer remains the most common nondermatologic cancer diagnosis and the second leading cause of cancer-related death. In 2010, breast cancer treatment costs were estimated at $16.5 billion, comprising 13 % of the burden of total cancer-related costs.2,3 Health care spending varies throughout the phases of breast cancer treatment, with ~23 % of total expenditures allocated during the initial episode of treatment (diagnosis and management during the first year), 41 % during continuing care, and 36 % during the last year of life.3,4 It has been estimated that surgical costs account for 25 % of breast cancer treatment expenditure among Medicare patients.5
An important contributor to health care costs includes deviations from the standard of care and variations in clinical practice that are not supported by evidence.6 Moreover, dramatic regional variations in health care spendi ...
- American Cancer Society. Breast cancer facts and figures, 2013–2014. Atlanta: American Cancer Society; 2013.
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–28. CrossRef
- Hassett MJ, Elkin EB. What does breast cancer treatment cost and what is it worth? Hematol Oncol Clin N Am. 2013;27:829–41. CrossRef
- Yabroff KR, Lund J, Kepka D, et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20:2006–14. CrossRef
- Warren JL, Yabroff, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100:888–97.
- McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635–45. CrossRef
- Brooks GA, Li L, Sharma DB, et al. Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013;105:634–42. CrossRef
- Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending, part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003;138:288–98. CrossRef
- Zuckermann S, Waidmann T, Berenson R, Hadley J. Clarifying sources of geographic differences in Medicare spending. N Engl J Med. 2010;363:54–62. CrossRef
- Berry SA, Doll MC, McKinley KE, Casale AS, Bothe A. ProvenCare: quality improvement model for designing highly reliable care in cardiac surgery. Qual Saf Health Care. 2009;18:360–8. CrossRef
- Fisher E, Anderson S, Tan-Chiu E, et al. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001;91:1679–87. CrossRef
- Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665–73. CrossRef
- Veronisi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer: long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg. 1990;211:250–6.
- Veronesi U, Volterrani F, Luini A, et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer. 1990;26:671–3. CrossRef
- Taghian A, Mohiuddin M, Jagsi R, Goldberg S, Ceilley E, Powell S. Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey. Ann Surg. 2005;241:629–39. CrossRef
- Azu M, Abrahamse P, Katz SJ, Jagsi R, Morrow M. What is adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol. 2010;17:558–63. CrossRef
- Morrow M, Harris JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer. Bigger is not better. N Engl J Med. 2012;367:79–82. CrossRef
- MacDonald S, Taghian AG. Prognostic factors for local control after breast conservation: does margin status still matter? J Clin Oncol. 2009;27:4929–30. CrossRef
- Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology–American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. doi:10.1245/s10434-014-3481-4.
- Veronesi U, Cascinellu N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002:347:1227–32. CrossRef
- Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41. CrossRef
- Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119:1402–11. CrossRef
- Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2013. doi:10.1001/jamasurg.2013.3049.
- McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in re-excision following breast conservation surgery. JAMA. 2012:307:467–75. CrossRef
- McCahill LE, Privette A, James T, et al. Quality measures for breast cancer surgery: initial validation of feasibility and assessment of variation among surgeons. Arch Surg. 2009;144:455–62. CrossRef
- Kotwall C, Ranson M, Stiles A, Hamann MS. Relationship between initial margin status for invasive breast cancer and residual carcinoma after re-excision. Am Surg. 2007;73:337–43.
- Waljee JF, Hu ES, Newman LA, Alderman AK. Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol. 2008;15:1297–303. CrossRef
- Menes TS, Tartter PI, Bleiweiss I, Godbold JH, Estabrook A, Smith SR. The consequence of multiple re-excisions to obtain clear lumpectomy margins in breast cancer patients. Ann Surg Oncol. 2005;12:881–5. CrossRef
- Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302:1551–6. CrossRef
- Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25:180–6. CrossRef
- Greenup RA, Camp MS, Taghian AG, et al. Cost comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol. 2012;19:3275–81. CrossRef
- Camp MS, Greenup RA, Taghian AG, et al. Application of ACOSOG Z011 criteria reduces perioperative costs. Ann Surg Oncol. 2013;220:836–41. CrossRef
- Brody H. Medicine’s ethical responsibility for health care reform—the top five list. N Engl J Med. 2010;362:283–5.
- Hassett MJ, Neville BA, Weeks JC. The relationship between cost, quality and outcomes among women with breast cancer in SEER/Medicare (abstract). J Clin Oncol. 2011;29:6001.
- Fisher ES, Bynum JP, Skinner JS. Slowing the growth of health care costs—lessons from regional variations. N Engl J Med. 2009;360:849–52. CrossRef
- Cost Implications of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
Annals of Surgical Oncology
Volume 21, Issue 5 , pp 1512-1514
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Surgical Oncology, Duke University Medical Center, Durham, NC, USA
- 2. Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA